News
Videos
Conferences
Events
Resources
Subscribe

|Videos|September 2, 2022

Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

Author(s)Sunandana Chandra, MD, MS

An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.

Episodes in this series

EP. 1 How Uveal Melanoma Differs from Cutaneous Melanoma

EP. 1 How Uveal Melanoma Differs from Cutaneous Melanoma

EP. 2 Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

EP. 2 Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

EP. 3 Historic and Current Treatment Options for mUM

EP. 3 Historic and Current Treatment Options for mUM

EP. 4 Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

EP. 4 Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

EP. 5 Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

EP. 5 Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

EP. 6 An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

EP. 6 An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

EP. 7 Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP. 7 Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP. 8 Advice for Patients Living with Metastatic Uveal Melanoma

EP. 8 Advice for Patients Living with Metastatic Uveal Melanoma

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration

September 20th 2024

Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors

September 20th 2024

Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs

September 13th 2024

CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making

September 13th 2024

LL Treatment Roadmap: Navigating First-Line Options With Your Doctor

September 6th 2024

Trending on CURE

FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma

Every FDA Oncology Approval From November 2025

11 Years Living With Stage 4 Cancer Inspires Gratitude and Reflection

What Patients Should Know About EGFR Mutated Lung Cancer Treatment

What Patients With AML Need to Know About Azacitidine and Venclexta

© 2025 MJH Life Sciences^®

All rights reserved.